for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Xencor Inc

XNCR.OQ

Latest Trade

43.02USD

Change

0.90(+2.14%)

Volume

1,700,539

Today's Range

41.64

 - 

43.79

52 Week Range

19.35

 - 

43.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
42.12
Open
42.50
Volume
1,700,539
3M AVG Volume
7.69
Today's High
43.79
Today's Low
41.64
52 Week High
43.79
52 Week Low
19.35
Shares Out (MIL)
57.24
Market Cap (MIL)
2,462.59
Forward P/E
-26.87
Dividend (Yield %)
--

Next Event

Q3 2020 Xencor Inc Earnings Release

Latest Developments

More

Xencor Reports Second Quarter 2020 Financial Results

Xencor Earns Milestone Payment From Morphosys For FDA Approval Of Monjuvi In U.S.

Xencor And Atreca Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Industry

Biotechnology & Drugs

Contact Info

111 W Lemon Ave

MONROVIA, CA

91016-2809

United States

+1.626.3055900

http://www.xencor.com/

Executive Leadership

Bassil I. Dahiyat

President, Chief Executive Officer, Founder and Director

John J. Kuch

Chief Financial Officer, Vice President

John R. Desjarlais

Senior Vice President, Research and Chief Scientific Officer

Allen Yang

Senior Vice President, Chief Medical Officer

Celia Eckert

Vice President, General Counsel, Corporate Secretary

Key Stats

1.83 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.2K

2020(E)

0.1K
EPS (USD)

2017

-1.050

2018

-1.310

2019

0.460

2020(E)

-1.573
Price To Earnings (TTM)
--
Price To Sales (TTM)
34.81
Price To Book (MRQ)
4.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-13.38
Return on Equity (TTM)
-12.07

Latest News

Latest News

BRIEF-Atreca And Xencor Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

* ATRECA AND XENCOR ENTER STRATEGIC COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL T CELL ENGAGING BISPECIFIC ANTIBODIES Source text for Eikon: Further company coverage:

BRIEF-Xencor And Atreca Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

* XENCOR AND ATRECA ENTER STRATEGIC COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL T CELL ENGAGING BISPECIFIC ANTIBODIES

BRIEF-Ecor1 Capital Reports 8.0% Passive Stake In Xencor Inc As Of June 8 - SEC Filing

* ECOR1 CAPITAL LLC REPORTS 8.0% PASSIVE STAKE IN XENCOR INC AS OF JUNE 8 - SEC FILING Source text: https://bit.ly/30Ou8Wd Further company coverage:

BRIEF-Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of XmAb 20717, PD-1 x CTLA-4 Bispecific Antibody, In Solid Tumors

* XENCOR REPORTS INITIAL DOSE-ESCALATION DATA FROM PHASE 1 STUDY OF XMAB®20717, PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN SOLID TUMORS

BRIEF-Xencor Reports First Quarter 2020 Financial Results

* Q1 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA

BRIEF-Xencor Posts Loss Per Share Of $0.47

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

CORRECTED-BRIEF-Marketaxess Holdings Set To Join S&P 500

* MARKETAXESS HOLDINGS SET TO JOIN S&P 500; AXON ENTERPRISE TO JOIN S&P MIDCAP 400; OTHERS TO JOIN S&P SMALLCAP 600

BRIEF-Xencor To Develop, Commercialize Il-15 Immune Activating Cytokines With Roche's Genentech

* XENCOR TO DEVELOP AND COMMERCIALIZE NOVEL IL-15 IMMUNE ACTIVATING CYTOKINES WITH GENENTECH

BRIEF-Xencor Regains Ex-U.S. Commercial Rights To Xmab®13676, Cd20 X Cd3 Bispecific Antibody

* XENCOR REGAINS EX-U.S. COMMERCIAL RIGHTS TO XMAB®13676, CD20 X CD3 BISPECIFIC ANTIBODY

BRIEF-Xencor Reports Q1 Loss Per Share $0.62

* Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S

BRIEF-Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share

* XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Xencor Files For Potential Mixed Shelf Offering

* XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text: (http://bit.ly/2G8MdV1) Further company coverage:

BRIEF-Xencor Announces Proposed Public Offering Of Common Stock

* XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Xencor Reports Q4 Loss Per Share $0.25

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors

* XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

BRIEF-Xencor posts Q3 loss of $0.33 per share

* Xencor reports third quarter 2017 financial results and provides clinical pipeline update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up